MicroLine is a small molecule commercialized by Eyenovia, with a leading Phase III program in Presbyopia. According to Globaldata, it is involved in 4 clinical trials, of which 3 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of MicroLine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for MicroLine is expected to reach an annual total of $62 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Pilocarpine (MicroLine) is under development for the treatment of presbyopia. It is administered topically to the eye with optejet microdose dispenser. It acts by targeting muscarinic acetylcholine receptor. It is a micro formulation of pilocarpine developed based on microdose array print (MAP) platform technology which delivers micro-dosing of the drug.
Eyenovia is an ophthalmic biopharmaceutical company. It discovers and develops treatments for eye diseases. It offers Optejet dispenser, a horizontal topical delivery system to administer eyedrop medications. It works in partnership with Arctic Vision Shanghai Biotechnology Co Ltd, Bausch Health Companies Inc, and Senju pharmaceutical Co Ltd to develop its products. The company brands includes eyenovia, optejet, MAP. Eyenovia is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$14 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$2 million in FY2020. The operating loss of the company was US$12.4 million in FY2021, compared to an operating loss of US$19.8 million in FY2020. The net loss of the company was US$12.8 million in FY2021, compared to a net loss of US$19.8 million in FY2020.
For a complete picture of MicroLine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.